Kyverna Therapeutics has released one-year follow-up data for its CAR-T candidate miv-cel in autoimmune disease, reporting sustained efficacy and no safety problems. The results arrive as two large pharmaceutical companies' autoimmune CAR-T programs have hit unexpected safety setbacks, according to Fierce Biotech.
The company describes the data as resetting the conversation around CAR-T for autoimmunity, and positions miv-cel as a potential first-in-class therapy. The report does not include specific efficacy figures or details on the rivals' safety issues, so the comparison rests on Kyverna's characterization.
This article is based on a single source, so there is no independent or conflicting account to weigh against it. The claims reflect Kyverna's announcement as covered by Fierce Biotech.